Inability of retroviral tests to identify persons with chronic fatigue syndrome, 1992.
Centers for Disease Control and Prevention (CDC) · MMWR. Morbidity and mortality weekly report · 1993
Quick Summary
In the early 1990s, some laboratories were offering blood tests to check if people with ME/CFS had been infected with certain viruses called retroviruses. This CDC study tested whether three of these commercial tests could actually tell the difference between people with ME/CFS and healthy people. The researchers found that these tests could not reliably distinguish between the two groups, meaning the tests were not accurate for identifying ME/CFS.
Why It Matters
This study is important because it demonstrated that commercial retroviral tests marketed to ME/CFS patients in the early 1990s were not scientifically valid. It highlights the need for rigorous evaluation of diagnostic tests before clinical implementation and protects patients from potentially unnecessary or misleading testing.
Observed Findings
Three retroviral assays failed to distinguish serologically between CFS case-patients and healthy controls
Commercial retroviral tests were being widely used clinically despite lack of confirmed evidence linking retroviruses to CFS
Tests marketed based on preliminary reports of HTLV-II-like retroviruses or spumaviruses did not show differential positivity between groups
The hypothesized association between retroviral infection and CFS had not been confirmed, yet testing continued
Inferred Conclusions
The evaluated retroviral tests lack diagnostic validity for ME/CFS and should not be relied upon to identify retroviral infection in CFS patients
Commercial test development and clinical implementation occurred without adequate scientific evidence supporting their use
Investigation of other potential etiologic factors and better-validated diagnostic approaches are needed for ME/CFS
Rigor in test validation is essential before marketing diagnostic assays for clinical use
Remaining Questions
What other methodological approaches might better detect retroviral involvement in ME/CFS, if any exists?
Why were these tests commercialized and adopted clinically without prior validation in case-control studies?
What This Study Does Not Prove
This study does not prove that retroviruses play no role in ME/CFS; rather, it shows that these three specific commercial tests were unable to detect any association if one existed. The failure to identify a retroviral connection with these assays does not establish that retroviruses are not involved in ME/CFS pathogenesis. It specifically challenges test accuracy, not the underlying hypothesis.